Trials / Recruiting
RecruitingNCT06580002
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.
Conditions
- Breast Cancer
- Sarcoma
- Gastric Cancer
- Lung Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Ovarian Cancer
- Liver Cancer
- Genitourinary Cancer
- Gynecologic Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riluzole | Given PO |
| DRUG | Placebo | Given PO |
Timeline
- Start date
- 2024-12-02
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2024-08-30
- Last updated
- 2025-06-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06580002. Inclusion in this directory is not an endorsement.